Jonathan Thompson, MD
Dr. Thompson is a medical oncologist who treats patients diagnosed with lung cancer, malignant pleural mesothelioma, thymoma, and thymic tumors. He practices at the Froedtert Hospital Cancer Center affiliated with the Medical College of Wisconsin in Milwaukee, Wisconsin.
Speaking of the care he provides, Dr. Thompson says, “The diagnosis of cancer is life-changing. Fortunately, the treatment of cancer and its symptoms are constantly improving through clinical trials. My goals are to provide compassionate care to all of my patients and to work closely with my patients and their loved ones to create the best care plans possible. I look to deliver the most up-to-date clinical care and to provide my patients access to promising clinical trials.”[1]
Education and Career
Dr. Thompson earned his medical degree at the Medical College of Wisconsin and completed his internship and residency in Internal Medicine at the Medical College of Wisconsin Affiliated Hospitals. He remained with the facility to complete a fellowship in Hematology and Oncology and then accepted the role of Assistant Professor and physician in the Cancer Center at Froedtert Hospital. He is board-certified in Internal Medicine, Hematology, and Medical Oncology.[1]
Research
Dr. Thompson’s research areas of interest are wide-ranging and include:[2]
- Biomarkers, Tumor
- Clinical Trial, Phase l and ll
- Mesothelioma
- Translational Medical Research
- Carcinoma, Non-Small-Cell Lung
- Small Cell Lung Carcinoma
- Immunotherapy
- Thymus Neoplasms
- Translational Medical Research
His recent publications include:[1]
· SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. (Borghaei H, de Marinis F, Dumoulin D, Reynolds C, Theelen WSME, Percent I, Gutierrez Calderon V, Johnson ML, Madroszyk-Flandin A, Garon EB, He K, Planchard D, Reck M, Popat S, Herbst RS, Leal TA, Shazer RL, Yan X, Harrigan R, Peters S, SAPPHIRE Investigators) Ann Oncol 2024 Jan;35(1):66-76 PMID: 37866811 SCOPUS ID: 2-s2.0-85178324517 10/23/2023
· Multicenter Phase 1b/2a Clinical Trial of Radioprotectant BIO 300 Oral Suspension for Patients With Non-Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy. (Simone CB 2nd, Serebrenik AA, Gore EM, Mohindra P, Brown SL, Wang D, Chetty IJ, Vujaskovic Z, Menon S, Thompson J, Fine G, Kaytor MD, Movsas B) Int J Radiat Oncol Biol Phys 2024 Feb 01;118(2):404-414 PMID: 37652301 SCOPUS ID: 2-s2.0-85172016695 09/01/2023
· Resected cytokeratin-negative small cell lung carcinoma. (Jain PV, Thompson J, Sheinin Y) BMJ Case Rep 2023 Apr 03;16(4) PMID: 37011997 PMCID: PMC10083812 SCOPUS ID: 2-s2.0-85151707665 04/04/2023
· Comprehensive genomic profiling: Does timing matter? (Thapa B, Ahmed G, Szabo A, Kamgar M, Kilari D, Mehdi M, Menon S, Daniel S, Thompson J, Thomas J, George B) Front Oncol 2023;13:1025367 PMID: 36865796 PMCID: PMC9971445 SCOPUS ID: 2-s2.0-85149381128 03/04/2023
· The AXL inhibitor, TP-0903, reverses EMT and shows activity in non-small cell lung cancer preclinical models (Joe R, Matsumura Y, Siddiqui A, Foulks J, Beg M, Thompson J, Yamamoto N, Spira A, Sarantopoulos J, Melear J, Lou Y, Lebedinsky C, Li J, Watanabe A, Warner S) European Journal of Cancer October 2022;174:S57-S58 SCOPUS ID: 2-s2.0-85140454116 10/01/2022
